Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?

Dongqiong Xiao¹, Xihong Li¹, Xiaojuan Su, Dezhi Mu, Yi Qu*

Department of Pediatrics/Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education), West China Second University Hospital, Sichuan University, Chengdu 610041, China

A R T I C L E   I N F O

Article history:
Received 25 May 2020
Received in revised form 16 October 2020
Accepted 22 October 2020

Keywords:
SARS-CoV-2
Coronavirus
Vitamin D
Acute lung injury
ARDS

A B S T R A C T

A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has been confirmed as having the capacity to transmit from humans to humans, causing acute respiratory distress syndrome (ARDS) and acute lung injury. Angiotensin converting enzyme-2 (ACE2) is known to be expressed on type II pneumocytes. As a counter-regulatory arm of the renin–angiotensin system (RAS), ACE2 plays critical roles in the pathogenesis of ARDS and acute lung injury.

The affinity of the spike protein receptor binding domain (RBD) of SARS-CoV-2 for human ACE2 (hACE2) largely determines the degree of clinical symptoms after infection by SARS-CoV-2. Previous studies have shown that regulating the ACE2/RAS system is effective in the treatment of severe acute respiratory syndrome coronavirus (SARS-CoV)-induced ARDS and acute lung injury. Since ACE2 is the host cell receptor for both SARS-CoV-2 and SARS-CoV, regulating the ACE2/RAS system may alleviate ARDS and acute lung injury caused by SARS-CoV-2 as well as SARS-CoV. Vitamin D was found to affect ACE2, the target of SARS-CoV-2; therefore, we propose that vitamin D might alleviate ARDS and acute lung injury induced by SARS-CoV-2 by modulating ACE2.

© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction and general physiology

A novel coronavirus (severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) had caused 4,761,559 confirmed cases and 317,529 confirmed deaths worldwide, as of May 20, 2020 (https://www.who.int/emergencies/diseases/novel-coronavirus-2019). Many of the symptoms caused by SARS-CoV-2 are similar to those caused by severe acute respiratory syndrome coronavirus (SARS-CoV), especially acute respiratory distress syndrome (ARDS) (Li et al., 2020a). Previous studies have reported that ARDS is the primary cause of mortality and morbidity in intensive care units (ICUs) (Liu and Tan, 2020; Liu et al., 2020a, b). ARDS is associated with increased alveolar epithelial permeability and pulmonary microvascular endothelial permeability, pulmonary edema, and pulmonary fibrosis (Russell et al., 2020). The SARS-CoV envelope-anchored spike protein has been shown to bind to the host receptor and then induce virus replication, and different structures of the SARS-CoV spike protein may bind to different target receptors (Li et al., 2020a, b; Wu et al., 2020). Thus, the surface structure of the spike protein is particularly important for the development of antiviral strategies (Zumla et al., 2020).

SARS-CoV-2 is a β-genus, single-stranded enveloped RNA virus (Li et al., 2020a). The genome sequences suggest that SARS-CoV-2 is closely associated with SARS and related viruses that circulate in bats (Li et al., 2020b). Almost 25% of the confirmed coronavirus disease 2019 (COVID-19) patients have been reported as having severe and underlying comorbidities (Biscayart et al., 2020).

Evidence for the influence of angiotensin converting enzyme-2 (ACE2) on SARS-CoV-induced ARDS

The SARS epidemic occurred in southern China and caused more than 8000 cases of infection worldwide in 2002–2003, with an approximately 10% fatality rate (Li, 2013). The receptor-binding
motif (RBM) of the SARS-CoV spike protein connects directly with ACE2 residues (Gui et al., 2017; Pak et al., 2009) (Figure 1). Mutations in the RBM affect the interactions of the spike protein and ACE2. For example, mutations at residues 479 and 487 of the RBM control cross-species infections and human transmission of SARS-CoV, respectively (Ge et al., 2013; Li, 2013; Pak et al., 2009; Struck et al., 2012). Furthermore, the affinity of the spike protein receptor binding domain (RBD) for human ACE2 (hACE2) predominantly determines the degree of clinical symptoms caused by SARS-CoV (Gui et al., 2017; Mueller et al., 2012).

ACE2 has been found to be expressed on viral target cells, such as type II pneumocytes and enterocytes (Bertram et al., 2011). After SARS-CoV binds to ACE2, it triggers receptor-mediated endocytosis and the transport of virions into the endosomes of type II pneumocytes (Bertram et al., 2011; Gui et al., 2017; Haga et al., 2010). Next, the virus replicates in the host cells, leading to downregulation of ACE2 (Li et al., 2020b).

ACE2 is a novel ACE homologue that acts as a counter-regulatory arm of the renin–angiotensin system (RAS) (Imai et al., 2008). This molecule can convert angiotensin I (Ang I) to Ang1-9 and convert Ang II to Ang1-7 (Imai et al., 2008; Kuba et al., 2006). When Ang II binds to the AT1a receptor it induces increased alveolar epithelial permeability and pulmonary microvascular endothelial permeability, pulmonary edema, and pulmonary fibrosis. However, the opposite effects occur when Ang II binds to the AT2 receptor. In addition, as a counter-regulatory arm of RAS, ACE2-Ang1-7 can bind to the Mas receptor to inhibit the above process and thus protect against lung injury (Li et al., 2016). The balance of Ang II/Ang1-7 is commonly disrupted after infection with SARS-CoV; the ratio of Ang II/Ang1-7 is increased due to decreased expression of ACE2, which can lead to acute lung injury and ARDS (Wu, 2020) (Figure 2).

The SARS-CoV spike protein has been shown to bind to ACE2 and induce interleukin-8 (IL-8) release from lung cells by activating activation protein 1 (AP-1) (Chen et al., 2010). Dysregulation of inflammatory cytokines may be involved in ARDS. High levels of proinflammatory cytokines, such as transforming growth factor β (TGFβ), IL-8, IL-6, tumor necrosis factor alpha (TNF-α), interferon alpha (IFN-α), IFN-β, IFN-γ, chemokine (C-C motif) ligand 3 (CCL3), CCL5, and CXCL10, have been detected in SARS-CoV infection (Castilletti et al., 2005; Chen et al., 2010; Zhang et al., 2004; Ziegler et al., 2005). CCL2 is associated with ARDS and pulmonary fibrosis (Chen et al., 2010). CCL2 is overexpressed in SARS patients. Chen et al. (2010) reported that SARS-CoV-induced casein II (CK II)-mediated phosphorylation of the ACE2 receptor activated ERK1/2 and upregulated AP-1/CCL2, thus leading to ARDS (Figure 3). Collectively, many studies have reported that ACE2 plays important roles in SARS-CoV-induced ARDS.

ACE2 protects the lung from acute injury

ACE2 overexpression can protect the lung from acute injury caused by viral and bacterial infections. Zou et al. demonstrated that H5N1 flu infection-induced lung injury could be alleviated by administrating recombinant hACE2 protein (Zou et al., 2014). Kuka et al. showed that higher levels of ACE2 are associated with better outcomes for coronavirus diseases (Kuba et al., 2006). In addition, overexpression of ACE2 alleviated lipopolysaccharide (LPS)-induced ARDS by activating the Ang1-7/Mas signaling pathway (Li et al., 2016).

ACE2 might affect SARS-CoV-2-induced ARDS: laboratory studies

SARS-CoV-2 viral infection can cause ARDS and acute lung injury, which are similar to those caused by SARS-CoV (Jin et al., 2020). ACE2 is the host cell receptor for both SARS-CoV-2 and SARS-CoV (Li, 2013; Fan et al., 2020; Zhou et al., 2020). Importantly, when the RBD binds to hACE2 with strong affinity, the spike protein mediates viral entry into pneumocytes with high efficiency (Wan et al., 2020). Wrapp et al. (2020) found that the affinity of the SARS-CoV-2 spike protein for binding to ACE2 was almost 20 times higher than that of the SARS-CoV spike protein, explaining why SARS-CoV-2 has a higher infection rate than SARS-CoV.
CoV. A study by Bao et al. (2020) revealed that SARS-CoV-2 replication could be detected in the lungs of mice with hACE2 that had been infected with SARS-CoV-2. These mice presented the typical histopathology of interstitial pneumonia, with infiltration of high levels of macrophages and lymphocytes into the alveolar interstitium. In addition, SARS-CoV-2 antigens could be detected in bronchial epithelial cells, macrophages, and alveolar epithelia. However, the above phenomenon was not found in wild-type mice with SARS-CoV-2 infection, suggesting that ACE2 is the key factor mediating SARS-CoV-2-induced lung damage.

Since ACE2 is the target receptor for both SARS-CoV-2 and SARS-CoV, we hypothesize that the pathogenic mechanism of the two viruses might be very similar (Wu, 2020). Therefore, upregulating ACE2 and inhibiting RAS may alleviate ARDS and acute lung injury caused by SARS-CoV-2 as well as SARS-CoV (Wu, 2020). Xie et al. (2006) investigated ACE2 expression in the lungs of a rodent model. These researchers found that the decrease in ACE2 was relatively slight between the young adult and the middle-aged groups, but the decrease was significant in older male rats compared with younger rats. This decrease in ACE2 with age may parallel the increase in COVID-19-related mortality in the older population.

**ACE2 might affect SARS-CoV-2-induced ARDS: clinical studies**

As the host cell receptor for SARS-CoV-2, ACE2 exists as a dimer that includes the N-terminal peptidase domain (PD) and the C-terminal collectrin-like domain (CLD) (Zhang et al., 2020). The PD of ACE2 recognizes the spike protein of SARS-CoV-2, and the CLD of ACE2 is cleaved by proteases such as transmembrane serine protease 2 (TMPRSS2), thus promoting SARS-CoV-2 spike protein-mediated entry into cells (Senapati et al., 2020). Specifically, decreased expression of proteins such as ACE2 and TMPRSS2 in the airway epithelium in children may reduce viral entry, which might be the reason why SARS-CoV-2 leads to decreased lung injury in children compared with adults (Lingappan et al., 2020). A study by Bobeck et al. reported that Ang II, an inhibitor of the RAS system, was safely used in a COVID-19 patient with cardiomyopathy and vasodilatory shock, with a rapid improvement in her hemodynamics and vasopressor requirement without adverse effects (Bobeck et al., 2020). In addition, Cheng et al. found that 44 patients with ARDS tolerated rhACE2 (Cheng et al., 2020).

The role of ACE polymorphisms in COVID-19

Since the affinity of the spike protein of SARS-CoV-2 for ACE2 predominantly determines the symptoms of patients with COVID-19, ACE allele frequency might affect the morbidity, infection course, severity, and mortality of COVID-19 (Guo et al., 2020; Sieniko et al., 2020; Taha et al., 2020). A study by Guo et al. revealed that the ACE structure could be changed by altered amino acids in missense variants. The His378Arg (rs142984500) mutant is a weak enhancer and the Ser19Pro (rs73635825) mutant is a strong enhancer of SARS-CoV-2 S-protein binding. The His378Arg (rs142984500) mutant may not only reduce the activity of ACE2 peptidase but may also affect the process of SARS-CoV-2 S-protein and ACE2 binding. Additionally, the Ser19Pro (rs73635825) alteration may destabilize the helix of ACE2, affecting contact with the S-protein. Mutations such as Lys341Arg, Asp206Gly, Ile468Val, Arg219Cys/His, and Gly211Arg may significantly destabilize the local structure, and some of these mutations may have a minor effect on S-protein binding. The distribution of 12 characterized ACE2 missense variants in different populations was also identified by this study. Missense variants were present in East Asian (rs191860450), South Asian (rs75103885 and rs14877180), African (rs149039346, rs73635825, rs147311723, and rs138390800) and European (rs148771870) populations (Guo et al., 2020). These findings might help us to recognize individuals with an increased risk of COVID-19.

**Inflammatory cytokines induced by SARS-CoV-2**

The major cytokines induced by SARS-CoV-2 include IL-2, IL-4, IL-6, IL-7, IL-10, granulocyte colony stimulating factor (G-SCF), inducible protein-10 (IP-10), monocyte chemoattractant protein 1 (MCP-1), macrophage inflammatory protein 1 alpha (MIP1α), tumour necrosis factor α (TNF-α), and interferon-γ (IFN-γ), which were observed at high levels in severe COVID-19 patients (Hu et al., 2020; Song et al., 2020; Wang et al., 2020; Ye et al., 2020).

Collectively, SARS-CoV-2 primarily enters type II pneumocytes with ACE2 and replicates with the help of TMPRSS2. Next, the replicated SARS-CoV-2 induces a cytokine storm, contributing to hyperinflammation and alveolar edema, and ultimately leading to ARDS.

**Could SARS-CoV-2-induced lung injury be attenuated by vitamin D?**

Vitamin D3 is mainly produced in the skin after exposure to ultraviolet rays from sunlight (Teymoori-Rad et al., 2019). The active form of vitamin D, 1,25(OH)2D (1,25 dihydroxy vitamin D), binds to the vitamin D receptor (VDR) to play anti-inflammatory and immune regulatory roles (Gou et al., 2018; Xiao et al., 2019). VDR interacts with 1,25(OH)2D and then binds to vitamin D responsive elements (VDREs) to inhibit or promote the expression of target genes, such as enhancement of ACE2 expression (Cui et al., 2019). Vitamin D deficiency is associated with increased pulmonary inflammation and ARDS in a mouse model; however, its effect is unclear in humans. Fitzgerald et al. (2015) found that healthy volunteers with vitamin D deficiency had increased pulmonary inflammation after LPS inhalation.

Ilie et al. (2020) found a negative correlation between vitamin D level and the number of COVID-19 cases in some countries, including Iceland, Norway, Sweden, Finland, Denmark, the UK,
Ireland, the Netherlands, Belgium, Germany, France, Switzerland, Italy, Spain, Estonia, Czech Republic, Slovakia, Hungary, Turkey, and Portugal. Furthermore, a negative correlation between vitamin D levels and the number of confirmed deaths caused by COVID-19 was also found in this study. There have been no actual data from the Chinese COVID-19 outbreak in relation to vitamin D levels until now. Vitamin D deficiency is common worldwide in all age groups due to decreased sun exposure and cutaneous synthesis, especially in northern regions. In particular, vitamin D deficiency is common among people during the winter and spring (particularly in the northern communities), especially in older and obese people (Orwoll et al., 2009). We speculate that the outbreak of COVID-19 in winter and spring may be partly due to higher vitamin D deficiency in these seasons.

Many studies have reported that vitamin D plays an important role in viral infections, such as those of the cold virus (Martineau et al., 2019; Science et al., 2013), rhinovirus (Schogler et al., 2016), influenza virus (Khare et al., 2013; Lee et al., 2018; Schogler et al., 2016), respiratory syncytial virus (RSV) (Teymoori-Rad et al., 2019), and adenovirus (Teymoori-Rad et al., 2019). Therefore, vitamin D might attenuate SARS-CoV-2-induced lung injury.

**Vitamin D and acute lung injury**

**Vitamin D and ACE2/RAS**

ARDS and acute lung injury are associated with high fatality rates in patients affected by SARS-CoV-2 and SARS-CoV. ARDS and acute lung injury are associated with damaged pulmonary microvascular endothelial cells (PMVECs), which result in increased alveolar permeability and pulmonary edema (Su et al., 2004). The balance between the expression of ACE1 and ACE2 is closely related to the ratio of Ang II:Ang 1-7; an imbalance of Ang II:Ang1-7 can lead to acute lung injury (Gao et al., 2019; Queiroz-Junior et al., 2019; Wang et al., 2018).

Increasing evidence indicates that 1,25(OH)2D inhibits the RAS (Ali et al., 2018; Cui et al., 2019). The renoprotection of vitamin D is likely mediated by inhibiting the RAS, Ang II, and NF-κB, with a subsequent reduction in proinflammatory cytokines, such as IL-18 and TGF-β (Ali et al., 2018). After binding to Ang II, AT1aR triggers NADPH oxidase (Nox) activation and generates reactive oxygen species (ROS) (Cui et al., 2019). VDRAactivation can inhibit the RAS to mediate antioxidant and anti-inflammatory effects (Cui et al., 2019).

VDR is widely distributed in lung cells. Vitamin D can alleviate acute lung injury by regulating RAS signalling (Xu et al., 2017). Pretreatment with calcitriol, a vitamin D agonist, significantly alleviated LPS-induced acute lung injury by upregulating ACE2 and downregulating ACE1, Ang II, and AT1aR in an animal model (Xu et al., 2017) (Figure 4). Chronic vitamin D deficiency may activate the RAS and lead to lung fibrosis (Zhou et al., 2008).

**Vitamin D and inflammatory cytokines**

Vitamin D can significantly decrease inflammatory cytokines, such as TNF-α, IL-8, IL-6, and IFN-β, when exposed to influenza virus (Figure 3) (Khare et al., 2013). In addition, IFN-β was downregulated after RSV-infected human airway epithelial cells were treated with vitamin D (Hansdottir et al., 2010). IL-8, an endogenous chemotactic factor for neutrophils, is overexpressed in acute lung injury. Furthermore, 1,25(OH)2D3 can inhibit neutrophil infiltration and alleviate acute lung injury by downregulating IL-8 (Takano et al., 2011). Vitamin D/VDR signalling plays an important role in alleviating alveolar permeability and pulmonary edema by decreasing proinflammatory cytokines (Shi et al., 2016).

**Vitamin D and antimicrobial peptides**

Vitamin D can induce the expression of antimicrobial peptides, which also have antiviral activity. Vitamin D has been reported to bind to VDR and then increase the human cathelicidin peptide LL37 and human β-defensins (HBDs) in macrophages (Teymoori-Rad et al., 2019) (Figure 5). LL37 can modulate Toll-like receptor (TLR) signalling and regulate inflammation (Schogler et al., 2016).

Collectively, vitamin D and SARS-CoV-2 can affect the same target, ACE2. Vitamin D might alleviate acute lung injury and ARDS.
induced by SARS-CoV-2 by regulating the RAS/ACE2 pathway, inflammatory cytokines, and antimicrobial peptides (Future 5).

Role of vitamin D supplementation in COVID-19 patients

Vitamin D supplementation might serve as a treatment to improve clinical outcomes in COVID-19 patients. A previous report showed that 1,25(OH)D is inversely correlated with the risk of ARDS, heart failure, and diabetes mellitus (Grant et al., 2020). Ohaegbulam et al. (2020) reported four vitamin D-deficient COVID-19 patients who received treatment with vitamin D supplementation. The clinical outcomes included increased vitamin D levels, shorter lengths of hospital stay, lower oxygen requirements, and reduced inflammatory markers. A questionnaire-based study in Italy reported that vitamin D supplementation reduced the prevalence of COVID-19 infection (odds ratio 0.56; 95% confidence interval 0.32–0.99; p = 0.048) (Fasano et al., 2020).

Conclusion and future perspectives

Since ACE2 is the host cell receptor for both SARS-CoV-2 and SARS-CoV, regulating the ACE2/RAS system may alleviate lung injury caused by SARS-CoV-2 as well as SARS-CoV. Vitamin D was found to affect ACE2, the target of SARS-CoV-2. We speculate that vitamin D might alleviate lung injury induced by SARS-CoV-2 by upregulating ACE2, decreasing inflammatory cytokines, and increasing antimicrobial peptides. The efficacy of vitamin D in treatment of SARS-CoV-2 needs to be verified through more evidence-based medicine. In the future, we hope that randomized controlled clinical trials can be carried out to achieve this.

Ethical approval and consent to participate

Not applicable; review.

Consent for publication

Not applicable; review.

Clinical trial registration number and date if applicable

Not applicable; review.

Availability of data and material

No additional data are available.

Conflict of interest

The authors declare that they have no competing financial interests.

Funding sources

This work was supported by the National Science Foundation of China (81971433, 81971428, 82001593, 82071353) and a grant from the Clinical Discipline Program (Neonatology) from the Ministry of Health of China (1311200003303).

Author information

Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu 610041, China; Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu 610041, China.
Credit authorship contribution statement

Dongqiong Xiao: Conceptualization, Software, Validation, Investigation, Resources, Writing - original draft, Writing - review & editing. Xihong Li: Conceptualization, Software, Validation, Investigation, Resources, Writing - original draft, Writing - review & editing. Xiaojuan Su: Software, Validation, Investigation, Resources, Writing - review & editing. Dezhu Mu: Software, Validation, Investigation, Resources, Writing - review & editing. Visualization, Supervision, Funding acquisition. Yi Qu: Conceptualization, Software, Validation, Investigation, Resources, Writing - review & editing. Visualization, Supervision, Funding acquisition.

References

Ali RM, Al-Shorbagy MY, Helmy MW, El-Abhar HS. Role of Wnt4/beta-catenin, Ang II/TGF-beta, ACE2, NF-kappa B, and IL-18 in attenuating renal ischemia/ reperfusion-induced injury in rats treated with Vit D and pioglitazone. Eur J Pharm Biol 2018;83:81–76.
Bao L, Deng W, Huang B, Gao H, Liu J, Ren L, et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 2020;.
Bertram S, Glowacka I, Mueller MA, Lavender H, Guiss M, Nehrmeier J, et al. Clearance and activation of the severe acute respiratory syndrome coronavirus spike protein by human airway trypsin-like protease. J Virol 2011;85(24):13363–72.
Biscardi C, Angeli G, Ploveras S, Chaves AL, Slagenhaupf P, Rodriguez-Morales AJ. The next big threat to global health? 2019 novel coronavirus (2019-nCoV). What advice can we give to travellers?—Interim recommendations January 2020, from the Latin American society for Travel Medicine (SLANVI). Travel Med Infect Dis 2020; 101567.
Bobeck KA, Holtzclaw AW, Brown TE, Clark PA. Effective use of angiotensin II in coronavirus disease 19-associated mixed shock state: a case report. A.P.A Pract 2020;14(6):01221.
Castelli C, Bordi I, Lalle F, Rozza G, Pescia F, Agrati C, et al. Coordinate induction of IFN-alpha and -gamma by SARS-CoV also in the absence of virus replication. Virolology 2005;341(1):163–9.
Chen SY, Yang J, Wang H, Wu B, Yu T-C, Wei W-C, Lin S, et al. Upregulation of the chemokine (C-C motif) ligand 2 via a severe acute respiratory syndrome coronavirus spike-ACE2 signaling pathway. J Virol 2010;84(15):7703–12.
Cheng H, Wang Y, Wang QG. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 2020;92 (7):725–30.
Cui X, Xu P, Li G, Qiao Y, Han W, Geng C, et al. Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: role of renin-angiotensin system. Redox Biol 2019;26.
Fasano A, Cereda E, Barichella M, Cassani E, Ferri V, Zacchini AL, et al. COVID-19 in Parkinson’s disease patients living in Lombardy, Italy. Mov Disord 2020;35 (7):1065–73.
Fitzgerald M, Shyamsundar M, McNamee JJ, Thickett DR, O’Kane CM, McAuley DF. Vitamin D deficiency drives pulmonary inflammation in a human model of the acute respiratory distress syndrome induced by inhaled lipopolysaccharide in healthy volunteers. PloS One 2015;20(7):e9990–.
Gao X, Xu H, Zhang B, Tao T, Liu Y, Du D, et al. Interaction of N-acetyl-seryl-aspartyl-lysyl-proline with the angiotensin-converting enzyme 2-angiotensin-1(1–7). Mas axis attenuates pulmonary fibrosis in silicotic rats. Exp Physiol 2019;104 (10):1562–74.
Ge XY, Li J-L, Yang X-L, Chimura AA, Zhu G, Epstein JH, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 2013;503(7477):535–9.
Gou X, Pan L, Tang T, Gao H, Xiao D. The association between vitamin D status and tuberculosis in children: a meta-analysis. Medicine (Baltimore) 2018;97(35): e12179.
Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CR, Aliano J, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19: Infections and Deaths. Nutrients 2020;12(4).
Gui M, Song W, Zhou H, Xu J, Chen S, Xiang Y, et al. Cryo-electro microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for spike binding. Cell Res 2017;27(1):119–25.
Guo X, Chen Z, Xia Y, Liu W, Li H. Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2). J Transl Med 2020;18(4):121.
Haga S, Nagata N, Okamura T, Yamamoto N, Sata T, Yamamoto N, et al. TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds. Antiviral Res 2010;85(3):551–5.
Hardoletti S, Monich MM, Louni N, Powers L, Gerke A, Hummingway GW. Vitamin D decreases respiratory syncytial virus infection of NF-kappa B-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state. J Immunol 2010;184(2):965–74.
Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol 2020;.
Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. Rev Med Virol 2019;29(2).

Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol 2020;

Wang J, Jiang M, Chen X, Montaner LJ. Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. J Leukoc Biol 2020;108(1):17–41.

Wang Y, Wu H, Niu W, Chen J, Liu M, Sun X, et al. Tanshinone IIA attenuates paraquat-induced acute lung injury by modulating angiotensin-converting enzyme 2/angiotensin-1-7 in rats. Mol Med Rep 2018;18(3):2955–62.

Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 2020;

Wu Y. Compensation of ACE2 function for possible clinical management of 2019-nCoV-induced acute lung injury. Virologica Sinica 2020;

Xie XD, Chen JZ, Wang XX, Zhang FR, Liu YR. Age- and gender-related difference of ACE2 expression in rat lung. Life Sci 2006;78(19):2166–71.

Xu J, Yang J, Chen J, Luo Q, Zhang Q, Zhang H. Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system. Mol Med Rep 2017;16(5):7432–8.

Ye Q, Wang R, Mao J. The pathogenesis and treatment of the 'cytokine storm' in COVID-19. J Infect 2020;80(6):607–13.

Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J 2020;96(1137):403–7.

Zhang YC, Li J, Zhan YL, Wu LQ, Yu XY, Zhang WJ, et al. Analysis of serum cytokines in patients with severe acute respiratory syndrome. Infect Immun 2004;72(8):4410–5.

Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2 vitamin D3-dependent regulation of the renin-angiotensin system in 1 alpha-hydroxylase knockout mice. Kidney Int 2008;74(2):170–9.

Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;

Ziegler T, Matikainen S, Ronkko E, Osterlund P, Sillanpaa M, Siren J, et al. Severe acute respiratory syndrome coronavirus fails to activate cytokine-mediated innate immune responses in cultured human monocyte-derived dendritic cells. J Virol 2005;79(21):13880–5.

Zou Z, Yan Y, Shu Y, Cao R, Sun Y, Li X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun 2014;

Zumla A, Hui DS, Azhar EI, Memish ZA, Mueurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet (London, England) 2020;